{"id":54498,"date":"2023-03-05T21:03:11","date_gmt":"2023-03-05T20:03:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/egnite-inc-announces-groundbreaking-research-from-its-database-at-american-college-of-cardiology-conference-2023\/"},"modified":"2023-03-05T21:03:11","modified_gmt":"2023-03-05T20:03:11","slug":"egnite-inc-announces-groundbreaking-research-from-its-database-at-american-college-of-cardiology-conference-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/egnite-inc-announces-groundbreaking-research-from-its-database-at-american-college-of-cardiology-conference-2023\/","title":{"rendered":"egnite, Inc. Announces Groundbreaking Research from its Database at American College of Cardiology Conference 2023"},"content":{"rendered":"
\n

\n– Two Bodies of Research Led by Philippe G\u00e9n\u00e9reux, MD and Colleagues were Presented Today at 2023 ACC Annual Meeting –<\/i>\n<\/p>\n

\n– <\/i>Key Findings Demonstrate Increased Mortality Across All Degrees of Severity of Aortic Stenosis, Suggesting the Need to Re-Evaluate Currently Recommended Timing of Intervention, and Highlight the Importance of the Extent of Cardiac Damage as the Main Driver for Outcomes <\/i>–<\/i>\n<\/p>\n

ALISO VIEJO, Calif.–(BUSINESS WIRE)–#digitalhealth<\/a>—egnite, Inc.<\/a>, a leading digital health company for cardiovascular care, announces today two novel research studies were presented at the American College of Cardiology\u2019s 72nd Annual Scientific Session Together with the World Congress of Cardiology (ACC.23\/WCC) on March 5, 2023. The studies were led by renowned cardiologist Philippe G\u00e9n\u00e9reux and colleagues using egnite’s extensive real-world database of over one million patients from 24 leading teaching and non-teaching institutions across the United States.\n<\/p>\n

<\/a><\/p>\n

\n“These results further underscore the poor prognosis associated with untreated aortic stenosis of any severity and provide meaningful insights for the management of this patient population,\u201d says G\u00e9n\u00e9reux, Director of the Structural Heart Program of Morristown\u2019s Gagnon Cardiovascular Institute.\n<\/p>\n

\nThe first study<\/a> was recognized as one of the ACC\u2019s top research abstracts in valvular heart disease in 2023. This study was the first to validate aortic stenosis staging based on cardiac damage for untreated patients across all levels of aortic stenosis severity using egnite\u2019s extensive, multicenter real-world database.\n<\/p>\n

\nKey findings demonstrated:<\/b>\n<\/p>\n